Abstract | BACKGROUND: METHODS: RESULTS: We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-naïve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+). CONCLUSIONS:
Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.
|
Authors | Fable Zustovich, Alessandra Ferro, Giuseppe Lombardi, Patrizia Farina, Vittorina Zagonel |
Journal | Chemotherapy
(Chemotherapy)
Vol. 60
Issue 5-6
Pg. 294-9
( 2014)
ISSN: 1421-9794 [Electronic] Switzerland |
PMID | 25999127
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 S. Karger AG, Basel. |
Chemical References |
- Angiogenesis Inhibitors
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Bevacizumab
(therapeutic use)
- Brain Neoplasms
(diagnosis, drug therapy, secondary)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, drug therapy)
- Female
- Humans
- Lung Neoplasms
(diagnosis, drug therapy)
- Male
- Middle Aged
|